Table 2.

Histopathologic and IHC features of the xenografts and their respective donor tumors

Xenograft no.-subline no.DiagnosisARaPSAChromogranin AbSynaptophysinbUBE2CaCyclin D1aRBaKi-67a
79
Donor tumorAdCa9590negneg1105010
 MDA PCa 79AdCa9010cnegneg10<110015
117
Donor tumorAdCa with NE diff7080pospos15309010
MDA PCa 117-9AdCa with NE diff9510pospos205010010
130
Donor tumorAdCa9580negneg207010010
 MDA PCa 130AdCa8040negneg30709510
144
Donor tumorAdCa9040negneg520530
SCPC<1<1pospos600095
LCNEC<15pospos400N/A95
 MDA PCa 144-13SCPC00pospos600085
 MDA PCa 144-4LCNEC00pospos400095
146
Donor tumorAdCa9020negneg100020
SCPC00pospos400095
 MDA PCa 146-10SCPC00pospos500060
 MDA PCa 146-17SCPC00pospos300040
 MDA PCa 146-20SCPC00pospos400060
155
Donor tumorSCPC00pospos505250
 MDA PCa 155-2SCPC00pospos500030
 MDA PCa 155-9SCPC00pospos600040
 MDA PCa 155-12SCPC00pospos400040
 MDA PCa 155-16SCPC00pospos700050
170
Donor tumorAdCa9520negneg107010025
 MDA PCa 170-1AdCa10060negneg258010030
 MDA PCa 170-4AdCa9515negneg157510055
180
Donor tumorAdCa with NE diff905negpos202010030
 MDA PCa 180-11AdCa with NE diff950negpos253010070
 MDA PCa 180-14AdCa with NE diff1000negpos202510050
 MDA PCa 180-18AdCa with NE diff1005negpos155010060
 MDA PCa 180-21AdCa with NE diff1005negpos355010080
 MDA PCa 180-30AdCa with NE diff955negpos205010050

Abbreviations: DT, donor tumor; AdCa, adenocarcinoma; NE diff, neuroendocrine differentiation; neg, negative; pos, positive; N/A, not available.

  • aPercentage of positive cells.

  • bneg: ≤5% positive cells, pos: >5% positive cells.

  • cNote that some discrepancies between donor and xenograft IHC profiles exist, likely as a result of clonal selection in xenograft establishment. Nonetheless, all xenografts were shown to mirror the section of the donor tumor from which they were obtained.